María L. Amador

An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer

Belén Rubio‐Viqueira, Antonio Jimeno, George Cusatis et al. · Clinical Cancer Research · 2006 · 412 citations · Full text

Medicine, Oncology, Pharmacology +16

An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors

María L. Amador, Darin Oppenheimer, Sofía Perea et al. · Cancer Research · 2004 · 242 citations · Full text

Medicine, Oncology, Pharmacology +14

A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)

Luis Paz‐Ares, J. M. Sanchez, A. García et al. · Journal of Clinical Oncology · 2006 · 162 citations

Medicine, Oncology, Pharmacology +17

Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents

Antonio Jimeno, Belén Rubio‐Viqueira, María L. Amador et al. · Cancer Research · 2005 · 105 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

Eva Barragán, Pau Montesinos, Mireia Camós et al. · Haematologica · 2011 · 65 citations · Full text

Medicine, Hematology, Oncology +16